Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
INVESTING
Myriad Genetics Up on Strategic-Options Plan for Autoimmune Unit
By Vidhi Choudhary
Jan 6, 2021 10:20 AM EST
INVESTING
Myriad Genetics Up on Strategic-Options Plan for Autoimmune Unit
By Vidhi Choudhary
Jan 6, 2021 10:20 AM EST
PRESS RELEASES
IPM Launches Innovative Program For Rheumatoid Arthritis
By PR Newswire
Nov 30, 2020 11:00 AM EST
PRESS RELEASES
American Society Of Clinical Oncology Exclusively Cites MyChoice® CDx In New Recommendations For Patients With Advanced Ovarian Cancer
By GlobeNewswire
Aug 21, 2020 7:05 AM EDT
PRESS RELEASES
Myriad Genetics Announces Inducement Awards
By GlobeNewswire
Aug 14, 2020 4:05 PM EDT
PRESS RELEASES
Cerecor And Myriad Genetics Announce That Levels Of LIGHT, A Novel Cytokine, Were Highly Correlated With Disease Severity And Mortality In COVID-19 ARDS Biomarker Study
By GlobeNewswire
May 26, 2020 7:00 AM EDT
PRESS RELEASES
Myriad Receives FDA Approval Of MyChoice CDx® As Companion Diagnostic For Lynparza™ (olaparib) In Patients With Advanced Ovarian Cancer
By GlobeNewswire
May 11, 2020 7:05 AM EDT
PRESS RELEASES
Myriad Submits SPMA For BRACAnalysis® CDx As A Companion Diagnostic For Lynparza® In Metastatic Castration-resistant Prostate Cancer
By GlobeNewswire
Jan 21, 2020 7:05 AM EST
INVESTING
Myriad Genetics Spikes on FDA Approval of Pancreatic Cancer Diagnostic Test
By Tony Owusu
Dec 30, 2019 8:54 AM EST
INVESTING
Myriad Genetics Plummets as Earnings Trail Forecasts, Guidance Is Slashed
By Dan Weil
Nov 5, 2019 10:57 AM EST
MARKETS
Myriad Genetics Sinks on Fourth-Quarter Earnings and Revenue Miss
By Rob Lenihan
Aug 14, 2019 9:55 AM EDT
JIM CRAMER
Dropbox, Qualcomm, Skechers: 'Mad Money' Lightning Round
By Scott Rutt
Apr 19, 2018 6:37 AM EDT
JIM CRAMER
Technology Is Fueling Gains: Cramer's 'Mad Money' Recap
By Scott Rutt
Apr 19, 2018 6:27 AM EDT
JIM CRAMER
Emerson Electric, S&P Global, Ball Corp.: 'Mad Money' Lightning Round
By Scott Rutt
Feb 2, 2018 6:43 AM EST
JIM CRAMER
Don't Fall for the Downward Bias: Cramer's 'Mad Money' Recap
By Scott Rutt
Feb 2, 2018 6:23 AM EST
STOCKS
Morgan Stanley Just Found 37 Challenged Stocks That Still Have No Hope
By Kinsey Grant
Oct 26, 2017 12:52 PM EDT
HEALTH
Biotech Movers: Jazz Shares Lower Amid Notes Offering
By Armie Margaret Lee
Aug 18, 2017 9:56 AM EDT
HEALTH
Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma
By Armie Margaret Lee
May 3, 2017 10:09 AM EDT
STOCKS
Biotech premarket movers: Sage Therapeutics, Immunomedics, Myriad Genetics
By Armie Margaret Lee
Feb 13, 2017 9:24 AM EST
STOCKS
Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments
By Alicia McElhaney
Feb 8, 2017 10:00 AM EST
STOCKS
Tesaro drug delays recurrence of ovarian cancer, new clinical trial shows
By Adam Feuerstein
Oct 8, 2016 2:16 AM EDT
MARKETS
Will myriad genetics (mygn) stock react to price target cut at jefferies?
By Annie Palmer
Aug 11, 2016 2:46 PM EDT
STOCKS
5 big stocks to add to your buy list -- plus 2 to avoid
By Jonas Elmerraji
Aug 10, 2016 2:23 PM EDT
MARKETS
Myriad genetics (mygn) stock tumbles on q4 earnings miss, guidance
By Rachel Aldrich
Aug 10, 2016 9:51 AM EDT
STOCKS
Analysts' Actions -- Coach, SunPower, Wayfair, Yelp and More
By TheStreet Staff
Aug 10, 2016 8:15 AM EDT
